



LEI: 549300Q7EXQQH6KF7Z84

22 July 2024

**RTW Biotech Opportunities Ltd**

**Portfolio Company Update: Artiva Biotherapeutics prices IPO at \$167 million**

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Artiva Biotherapeutics ("Artiva") regarding its pricing of a \$116 million initial public offering ("IPO"). Artiva will trade on Nasdaq Global Market under the ticker "ARTV".

Artiva's IPO raised \$167 million by offering 13,920,000 shares at \$12.00 per share. The shares finished flat on the first day of trading. As at 30 June 2024, Artiva represented 0.13% of the Company's NAV.

Artiva is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The Company initially invested in Artiva's Series B round in February 2021.

Chris Liu, PhD, Senior Research Analyst at the Investment Manager said, "Artiva Biotherapeutics is diligently advancing its lead allogeneic natural killer (NK) cell therapy, AlloNK, through several clinical trials. Currently, AlloNK is undergoing a phase 1 trial for lupus nephritis and participating in a basket study across various autoimmune indications. The recent IPO underscores the significant potential impact of this groundbreaking therapy."

The full text of Artiva's announcement can be accessed on its website at: <https://artivabio.com/>.

**For Further Information**

**RTW Investments, LP**

**+44 20 7959 6361**

Woody Stileman, Managing Director, Business Development

[biotechopportunities@rtwfunds.com](mailto:biotechopportunities@rtwfunds.com)

Krishna McCune, Director, Investor Relations

**Buchanan (PR & Communications Adviser)**

**+44 20 7466 5107**

Charles Ryland

Henry Wilson

George Beale

**Deutsche Numis (Joint Corporate Broker)**

**+44 20 7260 1000**

Freddie Barnfield

Nathan Brown

Euan Brown

**BofA Securities (Joint Corporate Broker)**

**+44 20 7628 1000**

Edward Peel

Alex Penney

**Cadarn Capital (Distribution & IR Partner)**

**+44 73 6888 3211**

David Harris

\*\*\*\*\*

**Elysium Fund Management Limited**

**+44 14 8181 0100**

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

**Morgan Stanley Fund Services USA LLC**

**+1 914 225 8885**

**About Biotech Opportunities Ltd:**

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at [www.rtwfunds.com/rtw-biotech-opportunities-ltd](http://www.rtwfunds.com/rtw-biotech-opportunities-ltd) for more information.

\*\*\*\*\*

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

\*\*\*\*\*

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCBLLFLZDLZBBB